Overhauled AERS II System Will Be Overseen By Bioinformatics Board

 
• By The Tan Sheet

A new Bioinformatics Board will oversee FDA's program to develop an advanced Adverse Event Reporting System with the capability to analyze data and assist medical reviewers in spotting safety signals

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet